J. Gathe

D. Musher, M. Rodriguez‐Barradas, R. Genta, 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Oral Atovaquone Compared with Intravenous Pentamidine for Pneumocystis carinii Pneumonia in Patients with AIDS

S. Follansbee, M. Dohn, S. Deresinski, 1994, Annals of Internal Medicine.

Resolution of severe cryptosporidial diarrhea with rifaximin in patients with AIDS.

J. Gathe, C. Mayberry, J. Němeček, 2008, Journal of acquired immune deficiency syndromes.

SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients

Edwin DeJesus, Jane Yeo, A. Gładysz, 2004, AIDS.

Virologic and Immunologic Outcomes in Patients Switched from Amprenavir to Fosamprenavir in a Clinical Practice Setting

J. Gathe, G. E. Pakes, J. E. Fuchs, 2010 .

Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inf

K. White, R. Ebrahimi, P. Tebas, 2014, The Lancet. Infectious diseases.

VERxVE 144 week results: nevirapine extended‐release (NVP XR) QD versus NVP immediate‐release (IR) BID with FTC/TDF in treatment‐naïve HIV‐1 patients

D. Podzamczer, J. Bogner, M. Nelson, 2012 .

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial

K. White, J. Rockstroh, B. Kearney, 2012, The Lancet.

The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial

C. Katlama, S. Staszewski, J. Eron, 2006, The Lancet.

Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised,

E. Negredo, C. Orkin, J. Eron, 2018, The lancet. HIV.

Adherence and Potency With Antiretroviral Therapy: A Combination for Success

J. Gathe, 2003, Journal of acquired immune deficiency syndromes.

Antiviral Activity of Enteric‐Coated Didanosine, Stavudine, and Nelfinavir Versus Zidovudine Plus Lamivudine and Nelfinavir

A. Cross, R. Badaró, A. Grimwood, 2002, Journal of acquired immune deficiency syndromes.

Safety and antiretroviral effects of combined didanosine and stavudine therapy in HIV-infected individuals with CD4 counts of 200 to 500 cells/mm3.

A. Cross, G. Beall, D. Peterson, 1999, Journal of acquired immune deficiency syndromes.

Surgical therapy for 101 patients with acquired immunodeficiency syndrome and symptomatic cholecystitis.

E. Bonefas, J. Gathe, E. L. Etter, 1997, American journal of surgery.

Efficacy of the protease inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24-week analysis from the RESIST-1 trial.

C. Farthing, D. Cooper, S. Walmsley, 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

A Once-Daily Lopinavir/Ritonavir-Based Regimen Provides Noninferior Antiviral Activity Compared With a Twice-Daily Regimen

D. Podzamczer, M. Johnson, M. King, 2006, Journal of acquired immune deficiency syndromes.

Efficacy and Safety of Nevirapine Extended-Release Once Daily versus Nevirapine Immediate-Release Twice-Daily in Treatment-Naive HIV-1-Infected Patients

D. Podzamczer, P. Cahn, A. Horban, 2011, Antiviral therapy.

Efficacy, Pharmacokinetics, and Safety Over 48 Weeks With Ibalizumab-Based Therapy in Treatment-Experienced Adults Infected With HIV-1: A Phase 2a Study

J. Gathe, S. Weinheimer, R. Hardwicke, 2021, Journal of acquired immune deficiency syndromes.

Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor–Based Single-Tablet Regimen for Initial HIV-1 Therapy: A Randomized Phase 2 Study

M. Saag, M. Das, J. Flamm, 2015, Journal of Acquired Immune Deficiency Syndromes.

Effect of gender and race on the week 48 findings in treatment‐naïve, HIV‐1‐infected patients enrolled in the randomized, phase III trials ECHO and THRIVE

W. Short, L. Mohapi, J. Gathe, 2012, HIV medicine.

Ethambutol-induced nephrotoxicity: case report and review of the literature

J. Varon, J. Gathe, S. Pablo, 2013 .

Recurrent small bowel infarction associated with antithrombin deficiency.

J. Gathe, R. Dekmezian, A. Golino, 1997, American Journal of Gastroenterology.

Human Immunodeficiency Virus in the State of Texas of the United States: Past Reflections, Present Shortcomings, and Future Needs of the Public Health Response

Camden J. Hallmark, U. Abbas, M. Rodriguez‐Barradas, 2020, Open forum infectious diseases.

Twice-daily amprenavir 1200 mg versus amprenavir 600 mg/ritonavir 100 mg, in combination with at least 2 other antiretroviral drugs, in HIV-1-infected patients

R. Pollard, J. Gathe, J. Nadler, 2003, BMC infectious diseases.

A Once-Daily Lopinavir/Ritonavir-Based Regimen Is Noninferior to Twice-Daily Dosing and Results in Similar Safety and Tolerability in Antiretroviral-Naive Subjects Through 48 Weeks

D. Podzamczer, M. Loutfy, S. Gibbs, 2009, Journal of acquired immune deficiency syndromes.

Patient-Reported Symptoms over 48 Weeks in a Randomized, Open-Label, Phase 3b Non-inferiority Trial of Adults with HIV Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF Versus Continuation of Ritonavir-Boosted Protease Inhibitor with Emtricitabine and Tenofovir DF

R. Speck, J. van Lunzen, S. Shreay, 2015, The Patient - Patient-Centered Outcomes Research.

International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK

Samit R. Joshi, Charlene A Flash, Thomas Lengauer, 2014 .

Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in a Rapid-Initiation Model of Care for Human Immunodeficiency Virus Type 1 Infection: Primary Analysis of the DIAMOND Study

R. Bolan, M. Ramgopal, R. Nettles, 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Dual Therapy Treatment Strategies for the Management of Patients Infected with HIV: A Systematic Review of Current Evidence in ARV-Naive or ARV-Experienced, Virologically Suppressed Patients

M. Gill, P. Cahn, S. Walmsley, 2016, PloS one.

Vicriviroc plus optimized background therapy for treatment-experienced subjects with CCR5 HIV-1 infection: final results of two randomized phase III trials.

Wayne Greaves, J. Slim, M. Nelson, 2012, The Journal of infection.

Beyond efficacy: the impact of combination antiretroviral therapy on quality of life.

P. Sax, J. Gathe, 2005, AIDS patient care and STDs.

Viral Suppression in the Setting of Multidrug Resistance to Nelfinavir,Tenofovir and Abacavir: A Case Report

J. Gathe, Meghann L Davis, R. Crutchley, 2017 .

Efficacy and safety of three doses of tipranavir boosted with ritonavir in treatment-experienced HIV type-1 infected patients.

D. Cooper, A. Lazzarin, D. Mayers, 2007, AIDS research and human retroviruses.

Comparison of renal changes with lopinavir/ritonavir plus raltegravir or tenofovir/emtricitabine in the PROGRESS study

C. Argyropoulos, L. Cotte, J. Gathe, 2014 .

B. Bernstein, J. Gathe, T. Podsadecki, 2010, Journal of acquired immune deficiency syndromes.

Safety and efficacy of ombitasvir – 450/r and dasabuvir and ribavirin in HCV/HIV-1 co-infected patients receiving atazanavir or raltegravir ART regimens

J. Slim, J. Eron, M. Sulkowski, 2014, Journal of the International AIDS Society.

Pharmacokinetic analysis of nevirapine extended release 400 mg once daily vs nevirapine immediate release 200 mg twice daily formulation in treatment-naïve patients with HIV-1 infection

D. Podzamczer, J. Mallolas, C. Orrell, 2017, HIV clinical trials.

Fatal Relapse of Myelodysplastic Syndrome in a Patient with HIV/Hepatitis C Coinfection Treated with Simeprevir/Sofosbuvir

J. Gathe, A. Glombicki, Benjamin Daquioag, 2017, Journal of the International Association of Providers of AIDS Care.

Elvitegravir/cobicistat/emtricitabine/tenofovir DF (Quad) has durable efficacy and differentiated safety compared to atazanavir boosted by ritonavir plus emtricitabine/tenofovir DF at week 96 in treatment‐naïve HIV‐1‐infected patients

J. Gathe, E. Dejesus, M. Fordyce, 2012 .

Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir df in the initial treatment of HIV infection

S. Chuck, C. Cohen, A. Mathias, 2011, AIDS.

Efficacy, Safety, and Tolerability of Etravirine With and Without Darunavir/Ritonavir or Raltegravir in Treatment-Experienced Patients: Analysis of the Etravirine Early Access Program in the United States

M. Gottlieb, J. Lalezari, J. Gathe, 2010, Journal of Acquired Immune Deficiency Syndromes.

The Major Genetic Determinants of HIV-1 Control Affect HLA Class I Peptide Presentation

R. C. Rose, Todd M. Allen, David S. Rubin, 2010, Science.

Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor–Based Single-Tablet Regimen for Initial HIV-1 Therapy: A Randomized Phase 2 Study

M. Saag, M. Das, J. Flamm, 2015, Journal of acquired immune deficiency syndromes.

Predictors of loss of virologic response in subjects who simplified to lopinavir/ritonavir monotherapy from lopinavir/ritonavir plus zidovudine/lamivudine.

B. Gazzard, M. King, C. Hicks, 2009, AIDS research and human retroviruses.